2024
Associations Between Genetic Risk, Physical Activities, and Distressing Psychotic-like Experiences
Ku B, Yuan Q, Arias-Magnasco A, Lin B, Walker E, Druss B, Ren J, van Os J, Guloksuz S. Associations Between Genetic Risk, Physical Activities, and Distressing Psychotic-like Experiences. Schizophrenia Bulletin 2024, sbae141. PMID: 39171674, DOI: 10.1093/schbul/sbae141.Peer-Reviewed Original ResearchPhysical activityPRS-SCZDistressing psychotic-like experiencesPsychotic-like experiencesDevelopment of psychosisMechanisms of physical activityGenetic liabilityParticipants of European ancestryPolygenic risk scoresIncome-to-needs ratioBody mass indexAssociated with trajectoriesAssociated with less riskAdolescent Brain Cognitive Development StudyAssociated with impaired functionFamily history of psychosisLinear mixed modelsGeneralized linear mixed modelsCognitive Development StudyHistory of psychosisEuropean ancestryGenetic riskFamily historyMass indexRisk score
2020
Reduced regulatory T cells with increased proinflammatory response in patients with schizophrenia
Sahbaz C, Zibandey N, Kurtulmus A, Duran Y, Gokalp M, Kırpınar I, Sahin F, Guloksuz S, Akkoc T. Reduced regulatory T cells with increased proinflammatory response in patients with schizophrenia. Psychopharmacology 2020, 237: 1861-1871. PMID: 32221694, DOI: 10.1007/s00213-020-05504-0.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsRegulatory T cellsHealthy controlsT cellsIL-17AIL-6Smoking status-matched healthy controlsCulture supernatant levelsT cell percentageTh1/Th2Levels of Foxp3Blood mononuclear cellsBody mass indexImmune imbalanceTreg percentageMass indexProinflammatory cytokinesMethodsForty patientsMononuclear cellsPlasma levelsProinflammatory responseSupernatant levelsCell percentageResultsIn comparisonArray kitA new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort)
Hark S, Jamain S, Schijven D, Lin B, Bakker M, Boland-Auge A, Deleuze J, Troudet R, Malhotra A, Gülöksüz S, Vinkers C, Ebdrup B, Kahn R, Leboyer M, Luykx J. A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort). Journal Of Psychopharmacology 2020, 34: 524-531. PMID: 32126890, PMCID: PMC7222287, DOI: 10.1177/0269881120907972.Peer-Reviewed Original Research
2019
Evidence for an association of serum melatonin concentrations with recognition and circadian preferences in patients with schizophrenia
Sahbaz C, Özer O, Kurtulmus A, Kırpınar I, Sahin F, Guloksuz S. Evidence for an association of serum melatonin concentrations with recognition and circadian preferences in patients with schizophrenia. Metabolic Brain Disease 2019, 34: 865-874. PMID: 30758707, DOI: 10.1007/s11011-019-00395-3.Peer-Reviewed Original ResearchConceptsBody mass indexSerum melatonin concentrationsPittsburgh Sleep Quality IndexHealthy controlsMelatonin concentrationsCognitive impairmentMorningness-Eveningness QuestionnaireHigher body mass indexLower MEQ scoresSleep Quality IndexNegative Syndrome ScaleEnzyme-linked immunosorbentCircadian preferenceMelatonin groupMass indexMelatonergic pathwaysHC groupPatientsNeurodevelopmental originSyndrome ScaleMelatonin levelsPatient samplesSchizophreniaMelatoninMEQ scores
2013
Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial
Tek C, Guloksuz S, Srihari VH, Reutenauer EL. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. BMC Psychiatry 2013, 13: 176. PMID: 23805859, PMCID: PMC3702521, DOI: 10.1186/1471-244x-13-176.Peer-Reviewed Original ResearchConceptsSevere mental illnessEfficacy of naltrexoneWeight gainOutcome measurementsHealth problemsMental illnessGreater New Haven areaTumor necrosis factor alphaWeight lossCurrent available medicationsPlacebo-controlled trialHigh-sensitivity CRPOpioid receptor antagonistSecondary outcome measuresSerum lipid profilePrimary outcome measurementBody mass indexD2 receptor blockadeEffects of naltrexoneNovel pharmacological optionsNecrosis factor alphaDoses of naltrexoneMajor health problemRates of obesitySignificant weight loss